Smith & Nephew SNATS Long Term Debt 2010-2024 | SNN
Smith & Nephew SNATS long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
- Smith & Nephew SNATS long term debt for the quarter ending June 30, 2024 was $2.319B, a 18.57% decline year-over-year.
- Smith & Nephew SNATS long term debt for 2023 was $2.319B, a 14.49% decline from 2022.
- Smith & Nephew SNATS long term debt for 2022 was $2.712B, a 4.78% decline from 2021.
- Smith & Nephew SNATS long term debt for 2021 was $2.848B, a 15.06% decline from 2020.
| Smith & Nephew SNATS Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2023 | $2,319 |
| 2022 | $2,712 |
| 2021 | $2,848 |
| 2020 | $3,353 |
| 2019 | $1,975 |
| 2018 | $1,301 |
| 2017 | $1,423 |
| 2016 | $1,564 |
| 2015 | $1,434 |
| 2014 | $1,666 |
| 2013 | $347 |
| 2012 | $430 |
| 2011 | $16 |
| 2010 | $642 |
| 2009 | $1,090 |
| Smith & Nephew SNATS Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2023-12-31 | $2,319 |
| 2023-06-30 | $2,633 |
| 2022-12-31 | $2,712 |
| 2022-06-30 | $2,281 |
| 2021-12-31 | $2,848 |
| 2021-06-30 | $2,916 |
| 2020-12-31 | $3,353 |
| 2020-06-30 | $2,476 |
| 2019-12-31 | $1,975 |
| 2019-06-30 | $1,980 |
| 2018-12-31 | $1,301 |
| 2018-06-30 | $1,420 |
| 2017-12-31 | $1,423 |
| 2017-06-30 | $1,604 |
| 2016-12-31 | $1,564 |
| 2015-12-31 | $1,434 |
| 2015-06-30 | $1,532 |
| 2014-12-31 | $1,666 |
| 2014-09-30 | $1,936 |
| 2014-06-30 | $1,986 |
| 2014-03-31 | $337 |
| 2013-12-31 | $347 |
| 2013-09-30 | $289 |
| 2013-06-30 | $335 |
| 2013-03-31 | $209 |
| 2012-12-31 | $430 |
| 2012-09-30 | $16 |
| 2012-06-30 | $15 |
| 2012-03-31 | $15 |
| 2011-12-31 | $16 |
| 2011-09-30 | $16 |
| 2011-06-30 | $18 |
| 2011-03-31 | $528 |
| 2010-12-31 | $642 |
| 2010-09-30 | $1,054 |
| 2010-06-30 | $1,045 |
| 2010-03-31 | $1,014 |
| 2009-12-31 | $1,090 |
| 2009-09-30 | $1,229 |
| 2009-06-30 | $1,267 |
| 2009-03-31 | $1,163 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $11.057B | $5.549B |
| Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $196.826B | 25.11 |
| Stryker (SYK) | United States | $146.166B | 32.94 |
| Boston Scientific (BSX) | United States | $145.408B | 41.81 |
| EssilorLuxottica (ESLOY) | France | $115.383B | 0.00 |
| Medtronic (MDT) | Ireland | $112.944B | 16.78 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.849B | 0.00 |
| Haleon (HLN) | United Kingdom | $41.827B | 27.18 |
| GE HealthCare Technologies (GEHC) | United States | $38.715B | 20.08 |
| ResMed (RMD) | United States | $35.199B | 28.92 |
| Terumo (TRUMY) | Japan | $27.980B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.250B | 18.56 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.811B | 13.89 |
| Insulet (PODD) | United States | $19.347B | 77.04 |
| Baxter (BAX) | United States | $15.818B | 10.29 |
| Bio-Rad Laboratories (BIO) | United States | $9.586B | 32.58 |
| BellRing Brands (BRBR) | United States | $9.323B | 37.51 |
| Demant (WILYY) | Denmark | $8.735B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.360B | 14.78 |
| ICU Medical (ICUI) | United States | $4.012B | 38.20 |
| Prestige Consumer Healthcare (PBH) | United States | $3.882B | 19.31 |
| Haemonetics (HAE) | United States | $3.691B | 18.01 |
| Envista Holdings (NVST) | United States | $3.413B | 25.42 |
| Perrigo (PRGO) | Ireland | $3.252B | 9.57 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.807B | 18.07 |
| GN Store Nord (GNNDY) | Denmark | $2.585B | 16.58 |
| Neogen (NEOG) | United States | $2.508B | 28.90 |
| LeMaitre Vascular (LMAT) | United States | $2.227B | 54.13 |
| AtriCure (ATRC) | United States | $1.876B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.572B | 27.52 |
| AdaptHealth (AHCO) | United States | $1.416B | 10.11 |
| InMode (INMD) | Israel | $1.410B | 8.48 |
| BioLife Solutions (BLFS) | United States | $1.213B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.205B | 0.00 |
| Owens & Minor (OMI) | United States | $1.124B | 8.78 |
| Curaleaf Holdings (CURLF) | Canada | $0.981B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.843B | 14.87 |
| CeriBell (CBLL) | United States | $0.754B | 0.00 |
| Evolus (EOLS) | United States | $0.666B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.623B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.557B | 24.58 |
| Omeros (OMER) | United States | $0.541B | 0.00 |
| Surmodics (SRDX) | United States | $0.527B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.434B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.434B | 0.00 |
| ZimVie (ZIMV) | United States | $0.394B | 33.23 |
| Valneva SE (VALN) | France | $0.355B | 0.00 |
| Quanterix (QTRX) | United States | $0.342B | 0.00 |
| Cerus (CERS) | United States | $0.332B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.317B | 30.18 |
| Biote (BTMD) | United States | $0.306B | 6.71 |
| Sanara MedTech (SMTI) | United States | $0.285B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.272B | 18.25 |
| High Tide (HITI) | Canada | $0.250B | 103.00 |
| Zynex (ZYXI) | United States | $0.245B | 51.20 |
| Canopy Growth (CGC) | Canada | $0.237B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.226B | 3.18 |
| Aurora Cannabis (ACB) | Canada | $0.211B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.211B | 14.56 |
| Organigram Holdings (OGI) | Canada | $0.196B | 0.00 |
| Brainsway (BWAY) | Israel | $0.192B | 102.30 |
| MacroGenics (MGNX) | United States | $0.188B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.168B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.150B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.77 |
| Veru (VERU) | United States | $0.143B | 0.00 |
| Jin Medical (ZJYL) | China | $0.143B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.130B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.87 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.092B | 0.00 |
| INLIF (INLF) | $0.078B | 0.00 | |
| InterCure (INCR) | Israel | $0.077B | 0.00 |
| Exagen (XGN) | United States | $0.070B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.069B | 35.33 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.058B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| Apyx Medical (APYX) | United States | $0.052B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.017B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 14.11 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |